Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
出版年份 2016 全文链接
标题
Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Volume 70, Issue 11, Pages 886-897
出版商
Wiley
发表日期
2016-10-14
DOI
10.1111/ijcp.12881
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
- (2016) Marc S. Sabatine et al. AMERICAN HEART JOURNAL
- Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
- (2016) Michel Farnier et al. ATHEROSCLEROSIS
- Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey
- (2016) Ž. Reiner et al. ATHEROSCLEROSIS
- Structure, function, and genetics of lipoprotein (a)
- (2016) Konrad Schmidt et al. JOURNAL OF LIPID RESEARCH
- The relationship between Lp(a) and CVD outcomes: a systematic review
- (2016) Carol A. Forbes et al. Lipids in Health and Disease
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice
- (2016) et al. European Journal of Preventive Cardiology
- Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus
- (2016) Satomi Yamamoto et al. PLoS Pathogens
- Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes
- (2016) Aarti Ramanathan et al. PLoS One
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
- (2015) Dean J. Kereiakes et al. AMERICAN HEART JOURNAL
- Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
- (2015) Maciej Banach et al. Archives of Medical Science
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
- (2015) Harold Bays et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2015) Brian R. Ott et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non – Pre-Diabetics
- (2015) Payal Kohli et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both
- (2015) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (
- (2014) Brendan M. Everett et al. AMERICAN JOURNAL OF CARDIOLOGY
- Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial
- (2014) Anders Green et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
- (2014) Jennifer G. Robinson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Novel metabolic biomarkers of cardiovascular disease
- (2014) Majken K. Jensen et al. Nature Reviews Endocrinology
- Apolipoprotein E–low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner
- (2014) Lance A. Johnson et al. NEUROBIOLOGY OF DISEASE
- More than Cholesterol Transporters: Lipoprotein Receptors in CNS Function and Neurodegeneration
- (2014) Courtney Lane-Donovan et al. NEURON
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Statins and Cognitive Function
- (2013) Karl Richardson et al. ANNALS OF INTERNAL MEDICINE
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. CIRCULATION
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
- (2013) B. G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications
- (2013) Seth S. Martin et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Statins and Cognition: A Systematic Review and Meta-analysis of Short- and Long-term Cognitive Effects
- (2013) Kristopher J. Swiger et al. MAYO CLINIC PROCEEDINGS
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
- (2012) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The Controversies of Statin Therapy
- (2012) J. Wouter Jukema et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
- (2011) Anna Albecka et al. HEPATOLOGY
- Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol
- (2011) Judith Hsia et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- (2011) Colin Baigent et al. LANCET
- Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
- (2011) Stephen J. Nicholls et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands
- (2009) A.H. Pijlman et al. ATHEROSCLEROSIS
- Low-Density Lipoprotein Cholesterol Concentrations and Death Due to Intraparenchymal Hemorrhage
- (2009) Hiroyuki Noda et al. CIRCULATION
- Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries
- (2009) Michel P. Hermans et al. CURRENT MEDICAL RESEARCH AND OPINION
- PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression
- (2009) Patrick Labonté et al. HEPATOLOGY
- Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease
- (2009) Marianne Abifadel et al. HUMAN MUTATION
- Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
- (2009) D. Steinberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Serum Cholesterol LDL and 90-Day Mortality in Patients With Intracerebral Hemorrhage
- (2009) José María Ramírez-Moreno et al. STROKE
- Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus
- (2008) X. Yang et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
- Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
- (2008) Anne B. Rossebø et al. NEW ENGLAND JOURNAL OF MEDICINE
- APCSK9Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
- (2008) Sekar Kathiresan NEW ENGLAND JOURNAL OF MEDICINE
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started